Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamainternmed.2021.1834 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of multimodal nutrition intervention on glucose and lipid parameters of Arfa Iron and Steel Company workers.
BMC Nutr
July 2025
Research Center for Food Hygiene and Safety, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Objective: This study investigated the impact of nutritional interventions on glycemic and lipid profile factors among workers.
Design & Participants: This prospective before-after study was conducted on 1097 employees of Arfa Iron and Steel Company, Yazd, Iran.
Setting: At baseline, anthropometric indices, and laboratory parameters including lipid profiles, liver enzymes, glucose factors, and blood pressure were measured for all participants.
GLP-1 Receptor Agonists in Diabetes and Obesity: A Case Report and Review of Bowel Obstruction Risks and Management.
Cureus
April 2025
Internal Medicine, Campbell University School of Osteopathic Medicine, Buies Creek, USA.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used for managing type 2 diabetes and obesity. These drugs improve glycemic control and promote weight loss, but they can cause gastrointestinal side effects such as gastroparesis and bowel obstruction, particularly in patients with preexisting GI motility issues. A 55-year-old woman with obesity, type 2 diabetes, and a history of small bowel obstruction developed severe abdominal pain and nausea after starting semaglutide.
View Article and Find Full Text PDFImprovement of Glycogenic Hepatopathy With Minimal Corresponding Improvement of Glycemic Control in a Person With Type 1 Diabetes: Case Report and Literature Review.
AACE Clin Case Rep
December 2024
Division of Endocrinology and Metabolism, University of Virginia School of Medicine, Charlottesville, Virginia.
Background/objective: Glycogenic hepatopathy is characterized by diffuse glycogen accumulation in hepatocytes that leads to hepatomegaly and elevated transaminases. Notably, the condition is reversible as improving glycemic control has been shown to resolve glycogenic hepatopathy and provide symptomatic relief.
Case Report: A 30-year-old female with longstanding and poorly-controlled type 1 diabetes presented to her primary care physician for a routine follow-up visit.
Minimising harms of tight glycaemic control in older patients with type 2 diabetes.
Afr J Prim Health Care Fam Med
December 2024
Department of Anaesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver.
In older adults with type 2 diabetes (T2DM), tight glycaemic control (HbA1c 7%) can result in more harm than benefit, especially when using insulin or sulfonylureas. Older adults are at higher risk for adverse drug events, especially hypoglycaemia, which may cause falls, confusion and hospitalisations. This Therapeutic Letter evaluates the risks of tight glycaemic control in older adults with T2DM, focusing on deprescribing diabetes medications in those over 65, especially those with multimorbidity and polypharmacy.
View Article and Find Full Text PDFBenefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes-A real-world study.
Diabetes Obes Metab
February 2025
Division of Endocrinology and Metabolism, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China.
Article Synopsis
- The study investigates the effects of combining pioglitazone, GLP1RA, and SGLT2i on metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes.
- Results from 888 patients showed that using more of these medications correlated with significant improvements in liver health, as measured by changes in the FAST score over a median follow-up of 3.9 years.
- Specifically, the combination of SGLT2i and pioglitazone was associated with the highest likelihood of achieving better FAST score outcomes, suggesting a promising approach for managing MASH in diabetic patients.